April 2022
In this podcast, Finnegan attorneys Mark Feldstein, Cora Holt, and Tom Irving discuss the impacts of the recent Federal Circuit cases GSK v. Teva and Amarin v. Hikma.
A closed captioning version is available here.
United States Court of Appeals for the Federal Circuit (CAFC), drugs, Food and Drug Administration (FDA)
Prosecution First Blog
January 27, 2023
Seminar
Patent Protection for Software-Related Inventions: Patent Law in Europe and the US
January 26, 2023
Oslo
Articles
Patent Infringement: When Is a Product Sold “Within the United States”?
November/December 2023
Articles
Strategic Intellectual Property Considerations for Protecting AI Innovations in Life Sciences
January 2023
Prosecution First Blog
Federal Circuit Clarifies the Standard of Review for Invalidity Challenges
January 13, 2023
Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
The Finnegan UPC Hub is a one-stop shop for our insights related to the Unified Patent Court (UPC).